Monte Rosa Therapeutics, Inc. (GLUE): Price and Financial Metrics


Monte Rosa Therapeutics, Inc. (GLUE): $8.10

0.32 (+4.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GLUE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GLUE Stock Price Chart Interactive Chart >

Price chart for GLUE

GLUE Price/Volume Stats

Current price $8.10 52-week high $45.56
Prev. close $7.78 52-week low $7.19
Day low $7.53 Volume 126,400
Day high $8.22 Avg. volume 259,743
50-day MA $11.33 Dividend yield N/A
200-day MA $18.78 Market Cap 378.01M

Monte Rosa Therapeutics, Inc. (GLUE) Company Bio


Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.


GLUE Latest News Stream


Event/Time News Detail
Loading, please wait...

GLUE Latest Social Stream


Loading social stream, please wait...

View Full GLUE Social Stream

Latest GLUE News From Around the Web

Below are the latest news stories about Monte Rosa Therapeutics Inc that investors may wish to consider to help them evaluate GLUE as an investment opportunity.

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the following upcoming investor conferences: Guggenheim Oncology Conference Virtual Fireside Chat 3:00 p.m. ET, Thursday, February 10 11th Annual SVB Leerink Global Healthcare Conference Virtual Fireside Chat 8:00 a.m. ET, Friday, February 18 Cowen’s 42nd Annual Health Care C

Yahoo | February 3, 2022

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders

BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science, which aims to accelerate the discovery and development of novel covalent molecular glue degraders leveraging CoLDR (covalent ligan

Yahoo | January 25, 2022

Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 5:15 p.m. ET on Tuesday, January 11, 2022. An archived webcast of the presentation can be accessed for up to 30 days via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.

Yahoo | January 4, 2022

Reviewing Monte Rosa Therapeutics (NASDAQ:GLUE) and Ocugen (NASDAQ:OCGN)

Monte Rosa Therapeutics (NASDAQ:GLUE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations and price targets for Monte Rosa []

Transcript Daily | December 7, 2021

Ocugen (NASDAQ:OCGN) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head to Head Analysis

Monte Rosa Therapeutics (NASDAQ:GLUE) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership. Insider and Institutional Ownership 28.5% of Ocugen shares are held by institutional investors. 3.7% of []

Dakota Financial News | December 5, 2021

Read More 'GLUE' Stories Here

GLUE Price Returns

1-mo -27.29%
3-mo -46.29%
6-mo -57.92%
1-year N/A
3-year N/A
5-year N/A
YTD -60.33%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3635 seconds.